今年，中国130家上榜公司的2024年营收总额约为10.7万亿美元；上榜中国企业的2024年平均利润从39亿美元提高到42亿美元，同比增加7.4%。 粤企新增1家，广州6家上榜 记者梳理发现，广东全省共有18家企业上榜今年的《财富》世界500强，相比去年新增1家企业——碧桂园控股有限公司于2024年跌出榜单后，今年重回 《财富》世界500强，最新排名460位。 总部位于广州的企业有6家上榜，分别是南方电网、广汽集团、广州工控集团、广新控股集团、广州建筑集团、广药集团。 7月29日，《财富》杂志发布2025年世界500强排行榜，130家中国企业进入榜单。按照上榜企业总部所在城市统计，广东全省共18家企业上榜，相比去年 新增1家企业。其中，总部位于广州市的企业有6家上榜。 130家中国企业上榜，平均利润同比增加7.4% 今年《财富》世界500强排行榜企业的营业收入总和约为41.7万亿美元，超过全球GDP的三分之一，比去年增长了约1.8%。此次上榜门槛（最低销售收 入）从321亿美元增长至322亿美元。所有上榜公司的净利润总和同比增长约0.4%，约为2.98万亿美元。500家上榜公司的资产总额和净资产总额均达到自 ...

证券之星消息，7月29日中药板块较上一交易日上涨1.0%，佛慈制药领涨。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。中药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002317 众生药业 | | 3.08亿 | 13.62% | -2.09亿 | -9.25% | -9887.67万 | -4.37% | | 300158 振东制药 | | 9631.85万 | 6.34% | -3070.18万 | -2.02% | -6561.68万 | -4.32% | | 686000 | 九芝堂 | 7562.48万 | 11.69% | 2336.98万 | 3.61% | -9899.45万 | -15.30% | | 002907 | 华森制药 | 6726.09万 | 9.79% | -650.70万 | -0.95% | -6075 ...

Government Guidance Funds - Hangzhou plans to establish a direct investment fund with a scale of 2 billion yuan, focusing on early-stage investments in technology startups, aiming to support at least 100 projects annually [5][6] - Fujian Province has launched a 1 billion yuan biopharmaceutical industry fund, targeting innovative drugs, vaccines, and medical devices [6] - Yunnan's new industry guidance fund has been established with a scale of 5 billion yuan, focusing on growth and mature non-listed enterprises [6] Market-oriented Funds - Suzhou Tai Meng No.1 Equity Investment Fund has completed registration with a total investment of 3.1 billion yuan, focusing on high-end manufacturing and health sectors [12] - Changshi Capital's hard technology phase III fund has raised 728 million yuan, targeting AI infrastructure and applications [12] - Shanghai Baoshan has launched a 500 million yuan AIC fund, focusing on new energy and high-end equipment manufacturing [13] Industry Funds - Guangzhou Baiyunshan Pharmaceutical Group plans to invest 1.4985 billion yuan in a biopharmaceutical fund, focusing on medical and healthcare sectors [16] - Shenhuo Co., Ltd. intends to invest 1.2 billion yuan in a high-quality industrial development fund, targeting new materials and intelligent manufacturing [17] - Guanghe Technology has committed 30 million yuan to a new industry fund focusing on AI and robotics [18]

Core Insights - Recent high temperatures have led to increased demand for summer health products, particularly heatstroke prevention and gastrointestinal medications [1] Offline Market Trends - Sales of heatstroke and gastrointestinal medications have surged, with some products seeing a nearly 50% month-on-month increase, such as Huoxiang Zhengqi Water [2] - Baiyunshan Banlangen Granules, a well-known product in the market, has experienced a sales peak, attributed to its recognized efficacy in preventing colds [2] Online Market Trends - Online platforms like Meituan have reported over 120% month-on-month growth in orders for heatstroke medications since July, with popular items including Huoxiang Zhengqi Oral Liquid and Shidizhu [3] - Meituan is actively promoting health initiatives during high-temperature periods, including free distribution of cooling medications to outdoor workers [3] Pharmacist Recommendations - Pharmacists advise that traditional Chinese medicine (TCM) should only be used for mild conditions and recommend consulting healthcare professionals before use [5] - Specific warnings are issued regarding the use of certain medications, such as Huoxiang Zhengqi Water and Shidizhu, which contain alcohol and are not suitable for certain populations [5]

Group 1 - The company has approved the registration of medium-term notes and ultra-short-term financing bonds for its subsidiary, Guangzhou Pharmaceutical Co., Ltd., with a total amount of up to RMB 16 billion and RMB 20 billion respectively [1][2][3] - The registration for the medium-term notes is valid for two years and will be underwritten by China Merchants Bank [2] - The registration for the ultra-short-term financing bonds is also valid for two years and will be co-underwritten by China Merchants Bank and Industrial Bank [3] Group 2 - The company plans to invest RMB 14.985 billion as a limited partner in the establishment of the Guangzhou Traditional Chinese Medicine Fund Phase II, accounting for 99.90% of the total subscription amount [6][8] - The total scale of the fund is RMB 15 billion, with the management being handled by Guangzhou Traditional Chinese Medicine Capital Private Fund Management Co., Ltd., a subsidiary of the company's controlling shareholder [6][10] - The fund aims to invest in the biopharmaceutical sector, focusing on projects that align with the company's strategic development [16][25]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. plans to invest 1.4985 billion RMB as a limited partner in the establishment of the second phase of the Guangzhou Traditional Chinese Medicine Fund, representing 99.90% of the total subscription amount [1][2][3] Summary by Sections Investment Overview - The total scale of the second phase of the Guangzhou Traditional Chinese Medicine Fund is 1.5 billion RMB, with the company contributing 1.4985 billion RMB [2][3] - The fund manager is Guangzhou Guangyao Capital Private Fund Management Co., Ltd., a subsidiary of the company's controlling shareholder, Guangzhou Pharmaceutical Group [1][4] Transaction Details - The investment does not constitute a major asset restructuring as defined by relevant regulations, and does not require shareholder approval [2][3] - The company has not exceeded 5% of its latest audited net assets in transactions with the same related party over the past 12 months, thus no shareholder meeting is required [2][4] Fund Structure and Management - The fund will focus on equity investments in the biopharmaceutical sector, aiming to generate investment returns [4][8] - The fund has a lifespan of 13 years, with a 10-year investment period and a 3-year exit period [4][6] Financial and Operational Impact - The investment is expected to enhance the company's capital operation capabilities and accelerate external investment efforts, contributing to the company's transformation and rapid development in the biopharmaceutical sector [8] - The investment will not significantly impact the company's current financial status or normal operations [8] Governance and Decision-Making - An investment decision-making committee will be established, consisting of three members, with voting rights equally distributed [6][7] - The company’s independent directors have approved the investment, affirming its fairness and alignment with the company's strategic goals [7][8]

证券代码：600332 证券简称：白云山 公告编号：2025－055 广州白云山医药集团股份有限公司 关于子公司中期票据和超短期融资券获准注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第八 次会议和 2023 年年度股东大会审议通过了《关于本公司控股子公司广州 医药股份有限公司申请注册中期票据及超短期融资券的议案》，同意提请 股东大会授权本公司控股子公司广州医药股份有限公司（"广州医药"） 在中国银行间交易商协会申请注册发行总额度不超过人民币 16 亿元的中 期票据及总额度不超过人民币 20 亿元的超短期融资券，在注册有效期内 分期择机发行事宜。具体内容详见本公司日期为 2024 年 3 月 15 日、2024 年 5 月 30 日的公告。 广州医药于今日收到中国银行间市场交易商协会（"交易商协会"） 出具的《接受注册通知书》（"通知书"）（中市协注【2025】MTN687 号、中市协注【2025】SCP195 号），交易商协会决定接受广州医药中期 票据、超 ...

证券代码：600332 证券简称：白云山 公告编号：2025－054 广州白云山医药集团股份有限公司 关于参与投资设立股权投资基金暨关联交易的公告 ●投资标的及交易内容：广州白云山医药集团股份有限公司（"本 公司"）拟作为有限合伙人以自有资金出资14.985亿元（人民币，下 同）参与设立广州广药基金二期股权投资合伙企业（有限合伙）（拟 定名，具体以企业登记机构核准的名称为准，"广药基金二期"、"基 金"），占广药基金二期认缴出资总额的99.90%。 ●广药基金二期的管理人为广州广药资本私募基金管理有限公 司（"广药资本"），广药资本是本公司控股股东广州医药集团有限 公司（"广药集团"）持股80%的控股子公司。广药资本作为执行事 务合伙人、基金管理人和普通合伙人认缴出资150.00万元。本公司副 董事长程宁女士担任广药资本的董事长。因此，本公司本次认购广药 基金二期份额构成关联交易。 ●本事项已经本公司第九届董事会第二十七次会议审议通过。本 公司本次认购基金份额不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 ●截至本公告披露日，过去12个月内本公司与同一关联人进行的 交易，扣除可以豁免提交股东大会 ...

Core Viewpoint - Baiyunshan (600332) plans to invest 1.498 billion yuan as a limited partner in the second phase of the Guangzhou Pharmaceutical Fund, representing 99.90% of the total committed capital of 1.5 billion yuan [1] Group 1: Investment Details - The total scale of the second phase of the Guangzhou Pharmaceutical Fund is 1.5 billion yuan, managed by Guangzhou Guangyao Capital Private Fund Management Co., Ltd. [1] - Baiyunshan's investment constitutes a related party transaction but does not qualify as a major asset restructuring [1] Group 2: Financial Indicators of Guangyao Capital - As of June 30, 2025, Guangyao Capital reported total assets of 27.9588 million yuan, net assets of 19.4081 million yuan, operating income of 10.5777 million yuan, and net profit of 3.6221 million yuan [1] - For the year ending December 31, 2024, total assets were 30.9367 million yuan, net assets were 15.786 million yuan, operating income was 15.7202 million yuan, and net profit was 5.2937 million yuan [1]

在区域分布上，上榜粤企主要集中于深圳（36家）、广州（21家）、佛山（8家）等城市，其中广深包 揽了上榜粤企前10名中的9席。 | 排名 ^ | 公司名称 ○ (中文) | 营业收入 ℃ (百万美元) | 利润 ℃ (百万美 | 关键 数据 | | --- | --- | --- | --- | --- | | | | | 元) | | | 111 | 怡和集团 | 35,779 | -468 | + | | 112 | 铜陵有色金属集团控股有限公司 | 35,773.5 | 175.2 | + | | 113 | 蜀道投资集团有限责任公司 | 35,732.8 | 533.9 | + | | | 114 广州市建筑集团有限公司 | 35,676 | 108.9 | + | | 115 | 广州医药集团有限公司 | 35,164.1 | 316.5 | + | | 116 | 碧桂园控股有限公司 | 35,128.6 | -4,563.5 | + | | 117 | 和硕联合科技股份有限公司 | 35,058.2 | 2528 | - | 据榜单发布方《财富》杂志统计，2025年上榜的500家中国公司，上榜门 ...